Q3 Earnings Forecast for SPRY Issued By Roth Capital

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Analysts at Roth Capital issued their Q3 2025 earnings per share estimates for shares of ARS Pharmaceuticals in a research report issued on Tuesday, November 4th. Roth Capital analyst K. Bauser anticipates that the company will post earnings per share of ($0.44) for the quarter. Roth Capital has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. Roth Capital also issued estimates for ARS Pharmaceuticals’ Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.70) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at $0.08 EPS, FY2028 earnings at $1.30 EPS and FY2029 earnings at $2.24 EPS.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Wednesday, August 13th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.05). The business had revenue of $15.72 million during the quarter, compared to analyst estimates of $12.92 million. ARS Pharmaceuticals had a negative net margin of 42.74% and a negative return on equity of 21.85%.

Several other research firms have also weighed in on SPRY. Raymond James Financial set a $32.00 price objective on ARS Pharmaceuticals in a research note on Friday, September 26th. Zacks Research lowered ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, July 26th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, ARS Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $31.80.

ARS Pharmaceuticals Stock Performance

SPRY opened at $9.05 on Thursday. The firm has a market cap of $894.41 million, a PE ratio of -18.47 and a beta of 0.83. The company has a quick ratio of 5.98, a current ratio of 6.17 and a debt-to-equity ratio of 0.37. The business has a fifty day simple moving average of $10.12 and a 200-day simple moving average of $13.66. ARS Pharmaceuticals has a fifty-two week low of $8.32 and a fifty-two week high of $18.90.

Insider Buying and Selling

In other ARS Pharmaceuticals news, CFO Kathleen D. Scott sold 12,500 shares of the business’s stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $15.00, for a total value of $187,500.00. Following the completion of the sale, the chief financial officer owned 10,042 shares of the company’s stock, valued at $150,630. The trade was a 55.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Richard E. Lowenthal sold 50,000 shares of the business’s stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $14.49, for a total value of $724,500.00. Following the completion of the sale, the chief executive officer directly owned 1,196,494 shares of the company’s stock, valued at $17,337,198.06. This represents a 4.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 112,500 shares of company stock worth $1,615,759. Corporate insiders own 33.50% of the company’s stock.

Institutional Trading of ARS Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC lifted its position in shares of ARS Pharmaceuticals by 243.7% in the third quarter. CWM LLC now owns 2,547 shares of the company’s stock worth $26,000 after buying an additional 1,806 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new position in shares of ARS Pharmaceuticals in the first quarter worth about $37,000. PNC Financial Services Group Inc. increased its stake in shares of ARS Pharmaceuticals by 78,100.0% in the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company’s stock worth $49,000 after purchasing an additional 3,905 shares during the period. Osaic Holdings Inc. increased its stake in shares of ARS Pharmaceuticals by 52.8% in the second quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock worth $91,000 after purchasing an additional 1,803 shares during the period. Finally, Ameritas Investment Partners Inc. increased its stake in shares of ARS Pharmaceuticals by 16.1% in the second quarter. Ameritas Investment Partners Inc. now owns 5,598 shares of the company’s stock worth $98,000 after purchasing an additional 777 shares during the period. Institutional investors and hedge funds own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.